The Journal of Experimental Medicine · 2020 · 207 citations · 16 references
Life SciencesImmunologyInfectious DiseasesEmerging Infectious DiseasesImmunology Of Infectious DiseasesVirologyAntiviral ImmunityAntiviral TherapyEmerging Viral DiseasesInterferon-based TherapyViral InfectionsViral PathogenesisAntiviral Innate SignalingAntiviral Interferon ResponsesInterferon Response To Viral InfectionSars-cov-2 Antiviral TherapyTreatment Of Coronavirus InfectionsType Iii Interferon ResponseType Iii Interferon SignalingViral Respiratory Infections
With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.
16
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta, Daniel F. McAuley, Michael Brown et al. · The Lancet · 2020 · 10.2K citations · Full text
IL-28, IL-29 and their class II cytokine receptor IL-28R
Paul O. Sheppard, Wayne Kindsvogel, Wenfeng Xu et al. · Nature Immunology · 2002 · 1.6K citations
Ioanna E. Galani, Vasiliki Triantafyllia, Evridiki-Evangelia Eleminiadou et al. · Immunity · 2017 · 487 citations · Full text